The pharmaceutical company’s stock surged nearly 6% during Thursday’s trading session to touch ₹20,072 per share on the BSE, crossing its previous high of ₹19,748.40 recorded in November 2025.

CDMO Growth, Commercial Pipeline and Margin Expansion Drive Investor Optimism; Pharma Stock Emerges as Market Favourite

Shares of Neuland Laboratories Limited have delivered a remarkable recovery in 2026, gaining strong investor attention after hitting a fresh record high on the back of improving business visibility and expectations of strong earnings growth.

The pharmaceutical company’s stock surged nearly 6% during Thursday’s trading session to touch ₹20,072 per share on the BSE, crossing its previous high of ₹19,748.40 recorded in November 2025.

From its 52-week low of ₹11,500 touched on March 23, 2026, the stock has rallied nearly 75%, making it one of the strongest performers in the pharmaceutical sector.

The sharp rally has also brought the stock into focus due to its presence in the portfolio of ace investor Mukul Mahavir Agrawal, who holds a significant stake in the company.

Neuland Laboratories Stock Performance: Strong Recovery in 2026

Neuland Laboratories has significantly outperformed broader market benchmarks during the current year.

Key Stock Highlights

Record high touched: ₹20,072
Previous peak: ₹19,748.40
52-week low: ₹11,500
Recovery from March low: Around 75%

The stock’s performance reflects growing investor confidence in the company’s ability to benefit from the expanding pharmaceutical outsourcing market.

While broader markets have remained volatile due to global uncertainties, pharma companies with strong specialised capabilities have continued to attract investor interest.

Mukul Agrawal’s Stake Adds Investor Interest

The stock gained additional attention after the latest shareholding data showed that investor Mukul Mahavir Agrawal holds a stake in Neuland Laboratories.

According to regulatory filings for the March 2026 quarter:

Mukul Agrawal held around 3.1% stake
Shareholding represented approximately 4 lakh equity shares

The company has not yet disclosed its June 2026 quarter shareholding pattern.

Mukul Agrawal is among the well-known investors tracked by the market for his investments in companies with strong growth potential and scalable business models.

Neuland Laboratories: Business Model and Growth Opportunity

Neuland Laboratories operates in the pharmaceutical industry with expertise in manufacturing:

Active Pharmaceutical Ingredients (APIs)
Complex molecules
Specialty pharmaceutical ingredients
Contract development and manufacturing services

The company serves global pharmaceutical companies and has developed capabilities in handling complex chemistry requirements.

Its business is divided broadly into API manufacturing and the fast-growing Contract Development and Manufacturing Organisation (CDMO) segment.

CDMO Business Becomes Key Growth Driver

The biggest growth opportunity for Neuland Laboratories lies in its CDMO business.

Global pharmaceutical companies are increasingly outsourcing research, development and manufacturing activities to specialised partners to improve efficiency and reduce costs.

Neuland is positioned to benefit from this trend due to:

Technical expertise
Complex molecule capabilities
Long-standing customer relationships
Manufacturing capabilities

The CDMO segment provides better growth visibility and potentially stronger margins compared with traditional API businesses.

Management Sees Strong Growth Visibility Ahead

During the Q4FY26 earnings conference call, Neuland Laboratories management highlighted a positive outlook for the coming years.

The company expects growth to be supported by:

Existing commercial products
Near-commercial molecules
Expansion of customer relationships
Increasing CDMO opportunities

Management indicated that the company has visible growth opportunities over the next two to three years through its existing pipeline.

Q1FY27 Earnings Expected to Show Strong Momentum

Brokerages tracking the pharmaceutical sector expect Neuland Laboratories to deliver strong performance in the June quarter of FY27.

According to JM Financial Institutional Securities, the CDMO segment is expected to remain the strongest growth contributor among pharma companies under its coverage.

The brokerage expects:

Strong revenue growth from CDMO operations
Improvement in EBITDA margins
Better profitability due to operating leverage

Neuland, along with other CDMO-focused companies, is expected to benefit from strong commercial order books.

Margin Expansion Could Boost Earnings Growth

One of the major factors supporting Neuland’s earnings outlook is expected margin improvement.

Analysts believe profitability could improve due to:

Commercial Portfolio Expansion

Higher contribution from commercial molecules could improve revenue quality.

Operating Leverage

Better utilisation of manufacturing facilities could support margins.

Product Mix Improvement

Growth in higher-value CDMO projects could improve overall profitability.

JM Financial expects significant EBITDA margin expansion due to the ramp-up of commercial projects.

Analyst View: Buy Rating With ₹22,913 Target Price

JM Financial has maintained a positive view on Neuland Laboratories and assigned a Buy rating on the stock.

The brokerage has set a target price of ₹22,913 per share.

The positive outlook is based on:

Strong CDMO pipeline
Commercialisation opportunities
Improving profitability
Long-term pharma outsourcing trend

Analysts believe Neuland has entered a stronger growth phase, supported by both existing projects and future opportunities.

Why CDMO Sector Is Attracting Investors

India’s pharmaceutical outsourcing industry is witnessing strong growth due to global supply chain diversification.

Key factors supporting CDMO growth include:

Global Pharma Companies Seeking Reliable Partners

Drug manufacturers are increasingly outsourcing production and development activities to specialised companies.

Complex Chemistry Advantage

Companies with expertise in difficult-to-manufacture molecules enjoy higher entry barriers.

Cost Advantage of Indian Companies

India offers skilled manpower, technical expertise and competitive manufacturing costs.

Growing Innovation Pipeline

New drug development opportunities are creating demand for specialised manufacturing partners.

Future Growth Drivers for Neuland Laboratories

Investors are closely watching several growth catalysts:

1. Expansion of CDMO Pipeline

Increasing customer projects could accelerate revenue growth.

2. Commercialisation of New Molecules

Successful launch of new products can improve earnings visibility.

3. Capacity Utilisation

Efficient use of manufacturing facilities will support profitability.

4. Global Customer Expansion

Adding new international clients could strengthen long-term growth.

Risks Investors Should Consider

Despite strong fundamentals, investors should remain aware of potential risks.

High Valuation After Sharp Rally

The stock has already delivered significant gains, making valuation an important factor.

Execution Challenges

Delays in commercialisation or project execution could impact growth expectations.

Regulatory Risks

Pharmaceutical companies operate under strict global regulatory frameworks.

Market Competition

Increasing competition in the CDMO sector could impact pricing and margins.

Investor Strategy: Growth Story Strong, But Track Valuation

Neuland Laboratories’ long-term growth opportunity remains attractive due to its CDMO positioning and strong pharmaceutical capabilities.

However, after a sharp 75% rally from its March low, investors should evaluate:

Earnings growth potential
Valuation comfort
New order additions
Margin improvement

Existing investors may continue monitoring business execution, while fresh investors may prefer a staggered approach rather than aggressive buying after a sharp price increase.

Conclusion: Neuland Laboratories Emerges as Pharma Growth Story

Neuland Laboratories’ record-high stock performance reflects growing confidence in its CDMO business, commercial pipeline and future earnings potential.

With global pharmaceutical outsourcing trends supporting demand, the company has several long-term growth opportunities.

However, after the strong rally, future stock performance will depend on the company’s ability to deliver consistent revenue growth, margin expansion and successful execution of its pipeline.